Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | APEX1 | P27695 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7148497 | 1.00 | ADRB2 (0.45) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL24370608 | 0.84 | CES2 (0.42) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL20833289 | 0.81 | CES2 (0.40) | CES2CES1GBA1 | |
| SCHEMBL7170117 | 0.80 | ADRA2C (0.46) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL28910421 | 0.79 | CES2 (0.45) | ADRA2AADRA2BADRA2CCES2CES1 | |
| SCHEMBL7153251 | 0.78 | ADRA2C (0.53) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL7171627 | 0.77 | ADRA2C (0.50) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL1206404 | 0.77 | ADRA2C (0.50) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL30288482 | 0.77 | ADRA2C (0.50) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL7150641 | 0.77 | ADRA2C (0.50) | ADRB2ADRA2AADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146483-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | NXERA PHARMA UK LIMITED (GB) | 2023-05-11 | — | — | US | disclosed |
| US-4224224-A | Certain 1-(carbocyclic aryl)-1-halo(or mesyloxy or tosyloxy)-2-(3'-alkoxycarbonylguanidino) ethanes | SYNTEX (U.S.A.) INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4172204-A | Method for preparing 4,5-dihydro-2-alkoxycarbonylamino-5-carbocyclic aryl imidazoles and intermediates thereof | SYNTEX (U.S.A.) INC. (US) | 1979-10-23 | — | — | US | disclosed |
| EP-0001500-A1 | 1-Carbocyclic aryl-2-mono or -bis(alkoxycarbonyl) guanidino ethanes, and methods for their preparation and the preparation therefrom of 4,5-dihydro-2-alkoxycarbonylamino-5-carbocyclic aryl imidazoles | SYNTEX (U.S.A.) INC. (US) | 1979-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146483-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | ADORA2A, ADORA1, ADORA3 | ADRB2 80/4885ADRA2A 41/4885ADRA2B 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.